# Medimscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medimscience

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.medimscience.com
- Total disclosed funding: $22M
- Latest round: Series A (Apr 2, 2026)
- Investors on record: 4

## About

Based in Hangzhou, China and founded in 2019, Hangzhou Myeloid Cure Biomedical Technology Co., Ltd., dba Medimscience, is a biotechnology company that engages in the research and development of macromolecular drug. Based on new targets on macrophages, the company develops first-in-class that promote tumor immune microenvironment reprogramming. In April 2026, Medimscience raised over CNY 150 million in Series A funding led by Kangjun Capital, with participation from Hongfeng Venture, Winfast Holding and other investors.

The company mainly provides tumor immunotherapy drugs, but also provides antibody drug research and development technical services, such as protein customization services, monoclonal antibody drug screening, etc.

The company generates revenue from the sales of medicine for macrophages in the tumor immune microenvironment.

## Funding rounds

- Series A, Apr 2, 2026, $22M — Kangjun Capital, Hongfeng Venture
- Angel, Jul 2, 2021 — Co-Win Ventures, Redhill Capital

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel
- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series A
- Hongfeng Venture (https://capitalatlas.ai/funds/hongfeng-venture) — Series A